ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Hope for Depression Sufferers: Spravato Delivers Relief in Just Two Hours.

Frisco, TX (Newsworthy.ai) Tuesday Apr 25, 2023 @ 9:00 AM Eastern —

A new depression medication called Spravato, which has recently undergone clinical trials, is showing great promise at providing relief from symptoms of depression in just a few hours. Symptoms associated with depression can include persistent feelings of sadness, lack of interest in activities once enjoyed, and thoughts of suicide.

Spravato offers new hope for those enduring depression symptoms and offers visible results in treating depression symptoms within just a couple of hours, offering hope and relief for people struggling with depression.

Spravato works by targeting glutamate receptors in the brain, restoring balance, and reducing depressive symptoms. This is the first new depression medication to be introduced in over 30 years. As such, it's expected to be a game-changer for millions of depression sufferers who haven't experienced relief with other traditional treatment methods.

Clinical trials have been conducted to test the effectiveness of Spravato, and the results show that participants experienced relief from depression symptoms in as little as two hours after receiving the medication. This is a significant improvement when compared to traditional treatment methods for depression, which can take weeks or even months to take effect.

Prime Psychiatry considers the potential of Spravato to help our patients manage their depression in a way that works quickly and effectively. Currently, they are recommending this medication for those with treatment-resistant depression, as it has shown great promise in those types of patients.

This breakthrough in depression medication offers renewed hope for those who have given up on finding an effective treatment for their symptoms. With this new option available, they can now experience relief from their symptoms in just a few hours, offering the prospect of a better quality of life.

About Prime Psychiatry

Prime Psychiatry is committed to providing individualized care using evidence-based principles. We provide psychiatric evaluations, medication management, Transcranial Magnetic Stimulation (for treatment of depression), Spravato, telepsychiatry, addiction treatment, disability evaluations and individual/couples counseling. Our services are offered to children, adolescents, and adults from 11–65-years. Prime Psychiatry was founded by Dr Efosa Airuehia, who is quadruple board certified in General Psychiatry, Child and Adolescent Psychiatry, Addiction Medicine and Lifestyle Medicine.


This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform™. Reference URL for this press release is here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.